A novel ERα-targeted hydrophobic tag degrader, overcomes tamoxifen resistance via unfolded protein response-induced apoptosis and homologous recombination repair inhibition in breast cancer
Bioorganic Chemistry · 2026-09 · 180 · 110129
DOI: 10.1016/j.bioorg.2026.110129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-09. Verfasst von Rong Shen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Bayi Road, Wuhan 430072, China. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Drug Resistance, Neoplasm, Breast Neoplasms, Tamoxifen. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Wuhan University, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Breast cancer (BC), predominantly ERα-positive, often develops resistance to endocrine therapy. We designed 20a, a novel ERα degrader based on the OBHSA scaffold with a hydrophobic amantadine tag. This compound demonstrates potent efficacy against both tamoxifen-sensitive and -resistant BC models in vitro and in vivo, with minimal systemic toxicity. Structural analysis reveals that 20a induces conformational changes in ERα (helixes 11-12), facilitating Hsp70 recruitment and subsequent ubiquitin-proteasome degradation. Additionally, 20a activates the ATF4-CHOP axis of the unfolded protein response, inducing apoptosis, while impairing homologous recombination repair through RAD51 degradation and BRCA1/2 downregulation. The latter effect creates synthetic lethality with Olaparib. Our findings elucidate the multi-mechanistic antitumor profile of 20a, highlighting its potential as a next-generation therapeutic for endocrine-resistant ERα-positive BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Bayi Road, Wuhan 430072, China.
- Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
- State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Hongshan Laboratory, Hubei Collaborative Innovation Center for Green Transformation of Bio-Resources, Hubei Key Laboratory of Industrial Biotechnology,…
- Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China. Electronic address: zhouhb@whu.edu.cn.
- Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Bayi Road, Wuhan 430072, China. Electronic address: jianhuang@whu.edu.cn.
Förderung
- Wuhan University
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Shen, R., Xin, L., Liu, J., Li, K., Deng, X., Liu, X., Wang, C., Min, J., Zhou, H. B., & Huang, J. (2026). A novel ERα-targeted hydrophobic tag degrader, overcomes tamoxifen resistance via unfolded protein response-induced apoptosis and homologous recombination repair inhibition in breast cancer. Bioorganic Chemistry, 180, 110129. https://doi.org/10.1016/j.bioorg.2026.110129
Vancouver
Shen R, Xin L, Liu J, Li K, Deng X, Liu X, et al. A novel ERα-targeted hydrophobic tag degrader, overcomes tamoxifen resistance via unfolded protein response-induced apoptosis and homologous recombination repair inhibition in breast cancer. Bioorganic Chemistry. 2026;180:110129. doi:10.1016/j.bioorg.2026.110129
BibTeX
@article{Shen2026,
author = {Shen, Rong and Xin, Lilan and Liu, Jing and Li, Kangkang and Deng, Xiaofei and Liu, Xin and Wang, Chao and Min, Jian and Zhou, Hai-Bing and Huang, Jian},
title = {A novel ERα-targeted hydrophobic tag degrader, overcomes tamoxifen resistance via unfolded protein response-induced apoptosis and homologous recombination repair inhibition in breast cancer},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {180},
pages = {110129},
doi = {10.1016/j.bioorg.2026.110129}
}
EUVIMED